Trump Announces U.S. Withdrawal from WHO, Raising Global Health Concerns

US
Published:

In a controversial move, President Donald Trump has announced that the United States will withdraw from the World Health Organization (WHO) and suspend foreign aid for three months. This decision, made through an executive order on his first day back in office, is set to take effect in 12 months, jeopardizing critical humanitarian efforts and the global battle against infectious diseases.

The U.S. is the largest financial contributor to the WHO, accounting for approximately 18% of the agency's funding. The organization had a budget of $6.8 billion for the years 2024-25, with American contributions playing a vital role in health initiatives worldwide, particularly in poorer and conflict-affected regions. The WHO has been instrumental in coordinating responses to various health crises including Ebola and polio.

In response, the WHO expressed regret over the announcement, emphasizing its crucial role in public health and security for all nations, including the U.S. German Health Minister Karl Lauterbach also criticized the decision, calling it a serious setback for global health initiatives and pledging to persuade Trump to reconsider.

Critics argue that the withdrawal will leave Americans vulnerable, as U.S. health sectors depend on WHO data for vaccine development and disease management. Public health experts warn that the decision may undermine international efforts to prepare for future pandemics and could hinder vital negotiations on global health agreements.

Trump justified the exit by claiming that the WHO has not acted independently and burdened the U.S. with disproportionate financial demands compared to other countries like China. However, experts warn that this could set a dangerous precedent and diminish U.S. leadership in global health.

The WHO has rejected Trump's allegations about its dealings with China and remains committed to its mission. As reactions from the international community unfold, the impact of this decision on global health efforts will likely be significant.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US
All United States News ->